Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:CMP-2-trimethylaminoethylphosphonate)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004291 AN007135 Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment Blood Plasmodium falciparum Malaria Monash University LC-MS
ST004290 AN007133 Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment Blood Plasmodium falciparum Malaria Monash University LC-MS
ST004153 AN006895 Multi-omics Study of Small Intestine Adaptation After Total Colectomy in a Rat model Feces Rat Shanghai Jiao Tong University LC-MS
ST004042 AN006681 Untargeted Metabolomics Identifies Oncometabolites Induced by P2-HNF4α Overexpression in Hepatocytes Cultured cells Mouse Cancer University of Tennessee Health Science Center LC-MS
ST003880 AN006373 Untargeted metabolome analysis of control and disease intervertebral disc tissue Tissue Human Bone disease Ganga Orthopaedic Research and Education Foundation LC-MS
ST002926 AN004798 Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002371 AN003866 High-resolution metabolomics analysis of NLRP3 inflammasome activated macrophages Macrophages Mouse Inflammation Wake Forest School of Medicine GC-MS
ST002309 AN003772 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002119 AN003467 Metabolomics analysis of zebrafish response to CID661578 treatment Larvae Zebrafish Diabetes North Carolina State University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002106 AN003444 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001788 AN002900 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University LC-MS
ST001611 AN002645 Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment Muscle Mouse Cancer North Carolina State University LC-MS
ST001611 AN002645 Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment Sarcoma Mouse Cancer North Carolina State University LC-MS
ST001549 AN002580 β-Adrenergic regulation of metabolism in macrophages (part-III) Macrophages Human Monash University LC-MS
ST001547 AN002576 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University LC-MS
ST001441 AN002407 Metabolomics of patient-derived fibroblasts Fibroblast cells Human Mitochondrial disease North Carolina State University LC-MS
ST001315 AN002190 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001304 AN002172 Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii Fibroblast cells Toxoplasma gondii Parasitic infection Monash University LC-MS
ST001276 AN002117 Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds Cultured cells Trypanosoma brucei Sleeping sickness Monash University LC-MS
ST001274 AN002115 Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) Cultured cells Trypanosoma brucei Sleeping sickness Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001202 AN002000 Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001201 AN001999 Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000539 AN000818 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) Cells Human Monash University LC-MS
ST000403 AN000642 Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes Cells Human Monash Institute of Pharmaceutical Sciences LC-MS
  logo